However, the pooled analysis of these two RCTs did not show a significant reduction in the risk of SCD or ventricular arrhythmias with PCSK9 inhibitors therapy, although a trend favoring treatment was observed. The gene discussed is PCSK9; the disease is Schnyder corneal dystrophy.